The focus of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Prostate Cancer (PC) Program is the development of new approaches to prostate cancer detection, diagnosis and treatment. The Program emphasizes a comprehensive basic and translational research approach to prostate cancer, embodied in three interactive Program scientific goals: 1) understanding the molecular genetics and epidemiology of prostate cancer, 2) elucidating the molecular underpinnings of prostate cancer, and 3) discovering and developing new prostate cancer therapies. Through advances in each of these goals, the Program has translated several discoveries into high-impact preclinical and clinical studies. The PC Program includes 30 Program members from four departments at the Johns Hopkins University School of Medicine (Oncology, Pathology, Radiation Oncology and Molecular Radiation Sciences, and Urology) and one from Howard University. The Program also closely interacts with the Cancer Immunology Program, the Cancer Molecular and Functional Imaging Program, and the Cancer Prevention and Control Program at the Johns Hopkins Bloomberg School of Public Health (Epidemiology). The research portfolio of the Program, which encompasses nearly all prostate cancer research at Johns Hopkins, receives support from the National Cancer Institute and other peer-reviewed funding sources, including a Prostate Cancer SPORE. The Program members have funding of $20.3 million total costs annually, of which $13.8 million total costs is peer-reviewed. Twenty-one Program members (70%) have peer-reviewed funding. Program trainees, both pre- and Postdoctoral, are supported by training grants from the SKCCC, the Department of Pharmacology and Molecular Sciences, and the Cellular and Molecular Medicine Program. Collectively, the PC Program membership has published 599 publications. The Program is highly interactive, with 245 (41%) Intra-Programmatic, 219 (37%) Inter-Programmatic and 238 (40%) multi-institutional collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-57
Application #
9944523
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
57
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Gordy, James T; Luo, Kun; Francica, Brian et al. (2018) Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3?-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother 41:181-189
Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Kyker-Snowman, Kelly; Erlanger Avigdor, Bracha; Nasim, Mansoor et al. (2018) A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. Breast Cancer Res Treat 170:425-430
Christenson, Eric S; Antonarakis, Emmanuel S (2018) PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 23:123-133
El-Diwany, Ramy; Soliman, Mary; Sugawara, Sho et al. (2018) CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. Sci Adv 4:eaat0843
Lee, Alice J; Montgomery, Madeline C; Patel, Rupa R et al. (2018) Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention. Sex Transm Dis 45:283-286
Bharathy, Narendra; Berlow, Noah E; Wang, Eric et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal 11:
Ambinder, Richard F (2018) A viral protein kinase drug target for tumors? J Clin Invest 128:2197-2198
Huang, Peng; Park, Seyoun; Yan, Rongkai et al. (2018) Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study. Radiology 286:286-295

Showing the most recent 10 out of 2393 publications